Summary Of Fda-022 - Clinical Trial

Chemical Name

Fda-022

CAS No.

--

Molecular Formula

--

Innovator

Developer

Indication

Solid Tumors

Therapeutic Area

Oncology

Market Status

--

Approval Year

Patent Expiry